Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist and expert in spectroscopy brings his scientific expertise in spectroscopy and materials research to support the company's development of innovative medical applications.
The appointment is expected to bolster Viromed's research capabilities, particularly in understanding the interaction between cold plasma and materials. Uwe Perbandt, CEO of Viromed Medical AG, commented, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he employs to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
With more than 180 publications and approximately 4,000 citations, Prof. Rubhausen has contributed to renowned scientific journals including Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. His interdisciplinary work also involves developing AI-supported analysis workflows for complex and high-dimensional datasets, a skill that could prove valuable in advancing cold plasma technology applications.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products. The company's operating business, listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. With a broad customer base in the DACH region and beyond, Viromed aims to further advance the use of cold plasma technology in medicine and capitalize on its growth potential.
The addition of Prof. Rubhausen signals Viromed's commitment to strengthening its scientific foundation and fostering innovation in cold plasma treatments. His expertise in spectroscopy and materials research is expected to enhance the company's ability to evaluate and refine its technology, potentially leading to new and improved medical solutions. For more information about Viromed Medical AG, visit their website.
